Latest news with #Merck&Co
Time of India
4 days ago
- Business
- Time of India
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda. The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on experimental cancer treatments and show that its success as Pfizer 's COVID-19 vaccine partner was not a one-off achievement. It also underscores a push across the pharma sector to master a new dual mechanism of action in oncology that activates the immune system - similar to an established drug class including Merck & Co's Keytruda - but which also cuts a tumour's blood supply. BioNTech's German-listed shares surged 16.7% by 1236 GMT to a six-week high. The two companies said in separate statements that the U.S. group will co-develop and co-commercialize BioNTech's drug, BNT327, for multiple solid tumour types. Live Events BioNTech's CEO and co-founder Ugur Sahin said the collaboration will serve "to accelerate and broadly expand BNT327's development to fully realize its potential." The companies said in presentation slides that Bristol Myers was bringing global networks in clinical development and manufacturing to the partnership, among other benefits. BioNTech said in a statement that the partners were seeking to set a new standard of care in the cancer market segment, now dominated by so-called checkpoint inhibitors including Keytruda with $29.5 billion in 2024 sales. Western drugmakers have struck a host of deals to win access to the new drug technology, known as PD-1/VEGF bispecific antibodies, which was pioneered in China. Pfizer last month partnered with China's 3SBio , paying $1.25 billion upfront and up to another $4.8 billion depending on developmental achievements. Merck & Co, whose Keytruda business is under threat from the sector's development push, in November last year licensed an early-stage cancer drug from China-based LaNova Medicines for up to $3.3 billion. "We are now starting to see an industry vote of confidence in the differentiation of this novel mechanism," BMO Capital Markets analysts said in a note. They welcomed BioNTech "partnering with a big pharma name to help manage a broad development plan and potential commercialization". Shares in Instil Bio, which is working with China's ImmuneOnco on a similar compound, soared 24% in U.S. trade on Monday. Summit Therapeutics and China's Akeso have formed another partnership in the development race with a drug candidate called ivonescimab. BioNTech took full ownership of BNT327 through the acquisition of China's Biotheus earlier this year for $800 million upfront and up to $150 million contingent on development achievements. It previously held certain rights in the drug under a 2023 collaboration deal. In addition to an initial payment of $1.5 billion, Bristol plans to pay BioNTech $2 billion in non-contingent anniversary payments through 2028. BioNTech may also earn up to $7.6 billion in development, regulatory and commercial milestones, Bristol said. The companies will share global profits and losses from the drug equally, and joint development and manufacturing costs will also be shared on a 50/50 basis, with some exceptions. BNT327 is being tested as a first-line treatment in extensive stage small cell lung cancer and non-small cell lung cancer. More than 1,000 patients have been treated with the drug to date. Economic Times WhatsApp channel )
Yahoo
30-05-2025
- Business
- Yahoo
Global Human Papillomavirus (HPV) Vaccine Market to Hit USD 27.36 Billion by 2032, Fueled by Cancer Prevention Initiatives and Expanding Immunization Coverage
U.S. HPV Vaccine Market to Surpass USD 10.96 Billion by 2032 Amid Strong Government Policies, Widespread Adoption, and Robust Pharmaceutical Innovation Austin, May 30, 2025 (GLOBE NEWSWIRE) -- Human Papillomavirus Vaccine Market Size & Growth Analysis: According to SNS Insider, The global Human Papillomavirus (HPV) vaccine market is projected to grow from USD 8.14 billion in 2024 to USD 27.36 billion by 2032, at a robust CAGR of 16.38% between 2025 and 2032. This growth is propelled by increasing public awareness of HPV-related cancers, the expansion of vaccination programs, and strong government support a Sample Report of Human Papillomavirus (HPV) Vaccine Market@ U.S. Market Outlook In the United States, the HPV vaccine market was valued at USD 3.44 billion in 2024 and is expected to rise to USD 10.96 billion by 2032. Key drivers include advanced healthcare infrastructure, government-backed vaccine mandates, and continued innovation from pharmaceutical leaders like Merck & Co. Market Dynamics Global momentum is building as healthcare authorities emphasize HPV prevention in public health agendas. HPV, the most common viral infection linked to cervical and other anogenital cancers, has become a top target for preventive healthcare. With widespread advocacy from organizations such as the CDC and WHO, vaccination rates are steadily increasing, especially among adolescents. Advancements in vaccine formulations—particularly polyvalent vaccines that offer protection against multiple HPV strains—are also contributing to market expansion. Additionally, collaborative efforts between public health agencies and private vaccine manufacturers have significantly improved vaccine accessibility and distribution. Human Papillomavirus (HPV) Vaccine Market Report Scope Report Attributes Details Market Size in 2024 US$ 8.14 billion Market Size by 2032 US$ 27.36 billion CAGR CAGR of 16.38% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Key Segments By Type (Bivalent, Polyvalent) By Disease Indication (HPV Related Cancer, Genital Warts) By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) Segment Highlights By Type: Polyvalent HPV vaccines led the market in 2024, accounting for over 85% of total revenue. Their broad-spectrum protection, exemplified by Merck's Gardasil 9, has made them the preferred choice among healthcare providers globally. This segment is also the fastest-growing, driven by healthcare professionals' growing preference for comprehensive immunization, improved global supply chains, and expanded funding in low- and middle-income countries. By Disease Indication: Vaccination against HPV-related cancers dominated in 2024, holding about 70% of the market share. This is due to increased recognition of the virus's role in cervical, anal, and oropharyngeal cancers. National and international cancer prevention strategies have embraced HPV vaccination as a key intervention. Meanwhile, the genital warts segment is growing rapidly as public health campaigns raise awareness of non-cancerous HPV effects and promote early vaccination. By Distribution Channel: Hospitals and retail pharmacies represented the largest distribution channels in 2024, capturing around 60% of the market. These outlets offer convenient access and are well-integrated into national immunization programs. Pharmacists and healthcare providers play a crucial role in promoting vaccine uptake. Online pharmacies and e-clinics are emerging as the fastest-growing channels, driven by telehealth growth, digital accessibility, and consumer demand for convenience and home-based services. Need Any Customization Research on Human Papillomavirus (HPV) Vaccine Market, Enquire Now@ Regional Insights North America remained the dominant market in 2024, supported by strong healthcare infrastructure, insurance coverage, and school-based vaccination programs. The presence of major pharmaceutical manufacturers further reinforces regional leadership. The Asia-Pacific region is witnessing the fastest growth, fueled by rising awareness, improved healthcare systems, and government-led initiatives. Countries like India, China, and Japan are increasing immunization budgets and implementing widespread campaigns, including India's national cervical cancer vaccination drive. Major Players Analysis Listed in this Report are: Merck & Co. Inc. GlaxoSmithKline plc (GSK) Serum Institute of India Pvt. Ltd. Sanofi Pasteur SA Pfizer Inc. Inovio Pharmaceuticals Inc. Walvax Biotechnology Co. Ltd. Bharat Biotech International Ltd. Johnson & Johnson Services Inc. Moderna Inc. Gilead Sciences Inc. Recent Developments January 2025: Merck faces a USD 8 billion lawsuit over Gardasil, with an active jury trial addressing alleged side effects and product safety. January 2025: GSK discontinued development of its Phase 2 HPV vaccine candidate, citing a lack of competitive advantage and efficacy potential. October 2024: The Indian government partnered with Serum Institute of India to launch Cervavac in a national immunization drive targeting adolescent girls. Buy a Single-User PDF of Human Papillomavirus (HPV) Vaccine Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Human Papillomavirus (HPV) Vaccine Market by Type 8. Human Papillomavirus (HPV) Vaccine Market by Disease Indication 9. Human Papillomavirus (HPV) Vaccine Market by Distribution Channel 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-05-2025
- Business
- Yahoo
Construction begins on MSD's $1bn biologics centre in Delaware, US
Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The 470,000ft² facility is set to bolster the company's biologics and therapy production, including antibody-drug conjugates (ADCs), featuring manufacturing, laboratory, and warehouse offerings. This move aims to diversify the company's product pipeline and bring critical medicines, such as Keytruda (pembrolizumab), closer to American patients. It is strategically positioned to become the future US production hub for the therapy. The investment in Delaware is part of the company's strategy to enhance its biologics portfolio and meet the growing demand for its pipeline products in the country. This centre is expected to generate more than 500 full-time positions and nearly 4,000 employment opportunities in construction. The lab component is anticipated to be completely operational by 2028, and the investigational compound production is expected to commence by 2030. MSD also plans potential site expansions, which could introduce an extra 1,500 full-time positions and 26,000 jobs in construction. Merck Wilmington Biotech's location at Chestnut Run Innovation & Science Park (CRISP) is said to not only contribute to the city's biotech sector growth but also leverage the talent pool from nearby universities in Delaware and Pennsylvania. The proximity to MSD's current facilities in Pennsylvania and New Jersey is also expected to offer opportunities for both current and prospective employees. MSD CEO and chairman Robert Davis said: 'The Merck Wilmington Biotech site represents our continued commitment to growing our investments in US manufacturing and has the potential to create thousands of high-paying American jobs while ensuring that we can produce and distribute products close to patients right here in the US.' MSD noted that following the 2017 Tax Cuts and Jobs Act, it has channelled over $12bn into enhancing US manufacturing and research capabilities. This includes the recent completion of a $1bn vaccine production facility in Durham, North Carolina, and a planned $3.5bn investment in biologics and small-molecule manufacturing sites, which will create an estimated 650 additional full-time positions. These efforts are projected to create over 37,600 construction-related jobs by 2028. "Construction begins on MSD's $1bn biologics centre in Delaware, US" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
30-04-2025
- Business
- Yahoo
Construction begins on MSD's $1bn biologics centre in Delaware, US
Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The 470,000ft² facility is set to bolster the company's biologics and therapy production, including antibody-drug conjugates (ADCs), featuring manufacturing, laboratory, and warehouse offerings. This move aims to diversify the company's product pipeline and bring critical medicines, such as Keytruda (pembrolizumab), closer to American patients. It is strategically positioned to become the future US production hub for the therapy. The investment in Delaware is part of the company's strategy to enhance its biologics portfolio and meet the growing demand for its pipeline products in the country. This centre is expected to generate more than 500 full-time positions and nearly 4,000 employment opportunities in construction. The lab component is anticipated to be completely operational by 2028, and the investigational compound production is expected to commence by 2030. MSD also plans potential site expansions, which could introduce an extra 1,500 full-time positions and 26,000 jobs in construction. Merck Wilmington Biotech's location at Chestnut Run Innovation & Science Park (CRISP) is said to not only contribute to the city's biotech sector growth but also leverage the talent pool from nearby universities in Delaware and Pennsylvania. The proximity to MSD's current facilities in Pennsylvania and New Jersey is also expected to offer opportunities for both current and prospective employees. MSD CEO and chairman Robert Davis said: 'The Merck Wilmington Biotech site represents our continued commitment to growing our investments in US manufacturing and has the potential to create thousands of high-paying American jobs while ensuring that we can produce and distribute products close to patients right here in the US.' MSD noted that following the 2017 Tax Cuts and Jobs Act, it has channelled over $12bn into enhancing US manufacturing and research capabilities. This includes the recent completion of a $1bn vaccine production facility in Durham, North Carolina, and a planned $3.5bn investment in biologics and small-molecule manufacturing sites, which will create an estimated 650 additional full-time positions. These efforts are projected to create over 37,600 construction-related jobs by 2028. "Construction begins on MSD's $1bn biologics centre in Delaware, US" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Bloomberg
23-04-2025
- Business
- Bloomberg
Cheaper Chinese HPV Vaccines Turn Merck's Gardasil From Boom to Bust
By , Karoline Kan, and Amber Tong Save Merck & Co. Chief Executive Officer Robert Davis was tired of talking about China. On an earnings call in February, he answered question after question about plunging demand for his company's vaccine against cancer-causing HPV in China, which previously powered Merck's growth.
